{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T04:53:33Z","timestamp":1794027213960,"version":"4.8.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,10,7]],"date-time":"2022-10-07T00:00:00Z","timestamp":1665100800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,10,7]],"date-time":"2022-10-07T00:00:00Z","timestamp":1665100800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Conquer Cystic Fibrosis","award":["Conquer Cystic Fibrosis Grant"],"award-info":[{"award-number":["Conquer Cystic Fibrosis Grant"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Multidrug resistant (MDR)\n                    <jats:italic>P. aeruginosa<\/jats:italic>\n                    accounts for 35% of all\n                    <jats:italic>P. aeruginosa<\/jats:italic>\n                    isolated from respiratory samples of patients with cystic fibrosis (CF). The usefulness of \u03b2-lactam antibiotics for treating CF, such as carbapenems and later generation cephalosporins, is limited by the development of antibacterial resistance. A proven treatment approach is the combination of a \u03b2-lactam antibiotic with a \u03b2-lactamase inhibitor. New \u03b2-lactam\/\u03b2-lactamase inhibitor combinations are available, but data are lacking regarding the susceptibility of MDR CF-associated\n                    <jats:italic>P. aeruginosa<\/jats:italic>\n                    (CFPA) to these new combination therapies. In this study we determined MIC values for three new combinations; imipenem-relebactam (I-R), ceftazidime-avibactam (CZA), and ceftolozane-tazobactam (C\/T) against MDR CFPA (n\u2009=\u200920). The MIC\n                    <jats:sub>90<\/jats:sub>\n                    of I-R, CZA, and C\/T was 64\/4, 32\/4, and 16\/8 (all \u00b5g\/mL), respectively. The susceptibility of isolates to imipenem was not significantly improved with the addition of relebactam (p\u2009=\u20090.68). However, susceptibility to ceftazidime was significantly improved with the addition of avibactam (p\u2009&lt;\u20090.01), and the susceptibility to C\/T was improved compared to piperacillin\/tazobactam (p\u2009&lt;\u20090.05) These data provide in vitro evidence that I-R may not be any more effective than imipenem monotherapy against MDR CFPA. The pattern of susceptibility observed for CZA and C\/T in the current study was similar to data previously reported for non-CF-associated MDR\n                    <jats:italic>P. aeruginosa.<\/jats:italic>\n                  <\/jats:p>","DOI":"10.1038\/s41598-022-21101-x","type":"journal-article","created":{"date-parts":[[2022,10,7]],"date-time":"2022-10-07T06:06:50Z","timestamp":1665122810000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Activity of newest generation \u03b2-lactam\/\u03b2-lactamase inhibitor combination therapies against multidrug resistant Pseudomonas aeruginosa"],"prefix":"10.1038","volume":"12","author":[{"given":"Robbie R.","family":"Haines","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Papanin","family":"Putsathit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine A.","family":"Hammer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna S.","family":"Tai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,10,7]]},"reference":[{"key":"21101_CR1","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1177\/2040622316641352","volume":"7","author":"C Edmondson","year":"2016","unstructured":"Edmondson, C. & Davies, J. C. Current and future treatment options for cystic fibrosis lung disease: Latest evidence and clinical implications. Ther. Adv. Chronic Dis. 7, 170\u2013183 (2016).","journal-title":"Ther. Adv. Chronic Dis."},{"key":"21101_CR2","unstructured":"Ahem, S. et al. The Australian Cystic Fibrosis Data Registry Annual Report, 2019. (2021)."},{"key":"21101_CR3","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1002\/ppul.24535","volume":"55","author":"J Milczewska","year":"2020","unstructured":"Milczewska, J. et al. Clinical outcomes for cystic fibrosis patients with Pseudomonas aeruginosa cross-infections. Pediatr. Pulmonol. 55, 161\u2013168 (2020).","journal-title":"Pediatr. Pulmonol."},{"key":"21101_CR4","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.biotechadv.2018.11.013","volume":"37","author":"Z Pang","year":"2019","unstructured":"Pang, Z., Raudonis, R., Glick, B. R., Lin, T.-J. & Cheng, Z. Antibiotic resistance in Pseudomonas aeruginosa: Mechanisms and alternative therapeutic strategies. Biotechnol. Adv. 37, 177\u2013192 (2019).","journal-title":"Biotechnol. Adv."},{"key":"21101_CR5","doi-asserted-by":"publisher","first-page":"S15","DOI":"10.1111\/j.1469-0691.1999.tb00719.x","volume":"5","author":"J-C Pech\u00e8re","year":"1999","unstructured":"Pech\u00e8re, J.-C. & K\u00f6hler, T. Patterns and modes of \u03b2-lactam resistance in Pseudomonas aeruginosa. Clin. Microbiol. Infect. 5, S15\u2013S18 (1999).","journal-title":"Clin. Microbiol. Infect."},{"key":"21101_CR6","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1128\/AAC.38.4.767","volume":"38","author":"DJ Payne","year":"1994","unstructured":"Payne, D. J., Cramp, R., Winstanley, D. J. & Knowles, D. J. Comparative activities of clavulanic acid, sulbactam, and tazobactam against clinically important beta-lactamases. Antimicrob. Agents Chemother. 38, 767\u2013772 (1994).","journal-title":"Antimicrob. Agents Chemother."},{"key":"21101_CR7","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1128\/CMR.00037-09","volume":"23","author":"SM Drawz","year":"2010","unstructured":"Drawz, S. M. & Bonomo, R. A. Three decades of beta-lactamase inhibitors. Clin. Microbiol. Rev. 23, 160\u2013201 (2010).","journal-title":"Clin. Microbiol. Rev."},{"key":"21101_CR8","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1007\/s40265-017-0725-1","volume":"77","author":"D Wong","year":"2017","unstructured":"Wong, D. & van Duin, D. Novel beta-lactamase inhibitors: Unlocking their potential in therapy. Drugs 77, 615\u2013628 (2017).","journal-title":"Drugs"},{"key":"21101_CR9","doi-asserted-by":"crossref","unstructured":"Humphries, R. M., Hindler, J. A., Wong-Beringer, A. & Miller, S. A. Activity of Ceftolozane-Tazobactam and Ceftazidime-Avibactam against Beta-Lactam-Resistant Pseudomonas aeruginosa Isolates. Antimicrob. Agents Chemother. 61, (2017).","DOI":"10.1128\/AAC.01858-17"},{"key":"21101_CR10","doi-asserted-by":"crossref","unstructured":"Sader, H. S., Flamm, R. K., Carvalhaes, C. G. & Castanheira, M. Antimicrobial Susceptibility of Pseudomonas aeruginosa to Ceftazidime-Avibactam, Ceftolozane-Tazobactam, Piperacillin-Tazobactam, and Meropenem Stratified by U.S. Census Divisions: Results from the 2017 INFORM Program. Antimicrob. Agents Chemother. 62, (2018).","DOI":"10.1128\/AAC.01587-18"},{"key":"21101_CR11","doi-asserted-by":"crossref","unstructured":"Carvalhaes, C. G., Shortridge, D., Sader, H. S. & Castanheira, M. Activity of Meropenem-Vaborbactam against Bacterial Isolates Causing Pneumonia in Patients in U.S. Hospitals during 2014 to 2018. Antimicrob. Agents Chemother. 64, (2020).","DOI":"10.1128\/AAC.02177-19"},{"key":"21101_CR12","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1093\/jac\/dkaa456","volume":"76","author":"S Mushtaq","year":"2021","unstructured":"Mushtaq, S., Meunier, D., Vickers, A., Woodford, N. & Livermore, D. M. Activity of imipenem\/relebactam against Pseudomonas aeruginosa producing ESBLs and carbapenemases. J. Antimicrob. Chemother. 76, 434\u2013442 (2021).","journal-title":"J. Antimicrob. Chemother."},{"key":"21101_CR13","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1111\/resp.12714","volume":"21","author":"DJ Smith","year":"2016","unstructured":"Smith, D. J. et al. Pseudomonas aeruginosa antibiotic resistance in Australian cystic fibrosis centres. Respirology 21, 329\u2013337 (2016).","journal-title":"Respirology"},{"key":"21101_CR14","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1099\/jmm.0.05324-0","volume":"53","author":"P Lanotte","year":"2004","unstructured":"Lanotte, P. et al. Genetic features of Pseudomonas aeruginosa isolates from cystic fibrosis patients compared with those of isolates from other origins. J. Med. Microbiol. 53, 73\u201381 (2004).","journal-title":"J. Med. Microbiol."},{"key":"21101_CR15","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1128\/CMR.15.2.194-222.2002","volume":"15","author":"JB Lyczak","year":"2002","unstructured":"Lyczak, J. B., Cannon, C. L. & Pier, G. B. Lung infections associated with cystic fibrosis. Clin. Microbiol. Rev. 15, 194\u2013222 (2002).","journal-title":"Clin. Microbiol. Rev."},{"key":"21101_CR16","doi-asserted-by":"publisher","first-page":"3492","DOI":"10.1128\/JB.00119-09","volume":"191","author":"M Starkey","year":"2009","unstructured":"Starkey, M. et al. Pseudomonas aeruginosa rugose small-colony variants have adaptations that likely promote persistence in the cystic fibrosis lung. J. Bacteriol. 191, 3492\u20133503 (2009).","journal-title":"J. Bacteriol."},{"key":"21101_CR17","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0096166","volume":"9","author":"B Ryall","year":"2014","unstructured":"Ryall, B. et al. The mucoid switch in Pseudomonas aeruginosa represses quorum sensing systems and leads to complex changes to stationary phase virulence factor regulation. PLoS ONE 9, e96166 (2014).","journal-title":"PLoS ONE"},{"key":"21101_CR18","doi-asserted-by":"publisher","first-page":"2022","DOI":"10.1093\/jac\/dkr232","volume":"66","author":"E Riera","year":"2011","unstructured":"Riera, E. et al. Pseudomonas aeruginosa carbapenem resistance mechanisms in Spain: Impact on the activity of imipenem, meropenem and doripenem. J. Antimicrob. Chemother. 66, 2022\u20132027 (2011).","journal-title":"J. Antimicrob. Chemother."},{"key":"21101_CR19","doi-asserted-by":"publisher","first-page":"2284","DOI":"10.1093\/jac\/dkz191","volume":"74","author":"SH Lob","year":"2019","unstructured":"Lob, S. H. et al. Activity of imipenem\/relebactam against MDR Pseudomonas aeruginosa in Europe: SMART 2015\u201317. J. Antimicrob. Chemother. 74, 2284\u20132288 (2019).","journal-title":"J. Antimicrob. Chemother."},{"key":"21101_CR20","doi-asserted-by":"publisher","first-page":"e35","DOI":"10.1016\/j.jcf.2021.03.007","volume":"21","author":"LJ Sherrard","year":"2022","unstructured":"Sherrard, L. J. et al. Emergence and impact of oprD mutations in Pseudomonas aeruginosa strains in cystic fibrosis. J. Cyst. Fibros. 21, e35\u2013e43 (2022).","journal-title":"J. Cyst. Fibros."},{"key":"21101_CR21","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1002\/phar.1622","volume":"35","author":"EJ Zasowski","year":"2015","unstructured":"Zasowski, E. J., Rybak, J. M. & Rybak, M. J. The \u03b2-lactams strike back: Ceftazidime-avibactam. Pharmacother. J. Hum. Pharmacol. Drug Ther. 35, 755\u2013770 (2015).","journal-title":"Pharmacother. J. Hum. Pharmacol. Drug Ther."},{"key":"21101_CR22","doi-asserted-by":"crossref","unstructured":"Ciofu, O. & Tolker-Nielsen, T. Tolerance and Resistance of Pseudomonas aeruginosa Biofilms to Antimicrobial Agents-How P. aeruginosa Can Escape Antibiotics. Front. Microbiol. 10, 913 (2019).","DOI":"10.3389\/fmicb.2019.00913"},{"key":"21101_CR23","doi-asserted-by":"publisher","first-page":"2894","DOI":"10.3389\/fmicb.2019.02894","volume":"10","author":"E Olivares","year":"2020","unstructured":"Olivares, E. et al. Clinical Impact of Antibiotics for the Treatment of Pseudomonas aeruginosa Biofilm Infections. Front. Microbiol. 10, 2894 (2020).","journal-title":"Front. Microbiol."},{"key":"21101_CR24","doi-asserted-by":"publisher","unstructured":"Castagnola, E. et al. Pharmacokinetics and pharmacodynamics of antibiotics in cystic fibrosis: a narrative review. Int. J. Antimicrob. Agents 106381 (2021). https:\/\/doi.org\/10.1016\/j.ijantimicag.2021.106381.","DOI":"10.1016\/j.ijantimicag.2021.106381"},{"key":"21101_CR25","doi-asserted-by":"publisher","first-page":"3650","DOI":"10.1128\/AAC.00174-09","volume":"53","author":"D Hubert","year":"2009","unstructured":"Hubert, D. et al. Continuous versus Intermittent Infusions of ceftazidime for treating exacerbation of cystic fibrosis. Antimicrob. Agents Chemother. 53, 3650\u20133656 (2009).","journal-title":"Antimicrob. Agents Chemother."},{"key":"21101_CR26","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1093\/jac\/dkx424","volume":"73","author":"PA Fraile-Ribot","year":"2018","unstructured":"Fraile-Ribot, P. A. et al. Mechanisms leading to in vivo ceftolozane\/tazobactam resistance development during the treatment of infections caused by MDR Pseudomonas aeruginosa. J. Antimicrob. Chemother. 73, 658\u2013663 (2018).","journal-title":"J. Antimicrob. Chemother."},{"key":"21101_CR27","doi-asserted-by":"crossref","unstructured":"Fr\u00f6hlich, C. et al. OXA-48-Mediated Ceftazidime-Avibactam Resistance Is Associated with Evolutionary Trade-Offs. mSphere 4, (2019).","DOI":"10.1128\/mSphere.00024-19"},{"key":"21101_CR28","doi-asserted-by":"publisher","first-page":"2508","DOI":"10.1093\/jac\/dkaa206","volume":"75","author":"MA Gomis-Font","year":"2020","unstructured":"Gomis-Font, M. A. et al. In vitro dynamics and mechanisms of resistance development to imipenem and imipenem\/relebactam in Pseudomonas aeruginosa. J. Antimicrob. Chemother. 75, 2508\u20132515 (2020).","journal-title":"J. Antimicrob. Chemother."},{"key":"21101_CR29","unstructured":"CLSI. Performance Standards for Antimicrobial Disk Susceptibility Tests, 11th Edition. CLSI Guideline M02. (Clinical and Laboratory Standards Institute, 2012)."},{"key":"21101_CR30","unstructured":"CLSI. Performance Standards for Antimicrobial Susceptibility Testing, 31st Edition. CLSI guideline M100. (Clinical and Laboratory Standards Institute, 2013)."},{"key":"21101_CR31","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1111\/j.1469-0691.2011.03570.x","volume":"18","author":"A-P Magiorakos","year":"2012","unstructured":"Magiorakos, A.-P. et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin. Microbiol. Infect. 18, 268\u2013281 (2012).","journal-title":"Clin. Microbiol. Infect."},{"key":"21101_CR32","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1186\/1471-2334-14-307","volume":"14","author":"MW Syrmis","year":"2014","unstructured":"Syrmis, M. W. et al. A comparison of two informative SNP-based strategies for typing Pseudomonas aeruginosa isolates from patients with cystic fibrosis. BMC Infect. Dis. 14, 307 (2014).","journal-title":"BMC Infect. Dis."},{"key":"21101_CR33","unstructured":"CLSI. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically, 11th Edition. CLSI guideline M07. (Clinical and Laboratory Standards Institute, 2018)."},{"key":"21101_CR34","unstructured":"Therapeutic Goods Administration. Australian Register of Therpeutic Goods. https:\/\/www.tga.gov.au\/australian-register-therapeutic-goods (2021)."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-21101-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-21101-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-21101-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,7]],"date-time":"2022-10-07T06:15:23Z","timestamp":1665123323000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-21101-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,7]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["21101"],"URL":"https:\/\/doi.org\/10.1038\/s41598-022-21101-x","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,7]]},"assertion":[{"value":"21 March 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 September 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 October 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"16814"}}